Impact of residual fluid on treatment outcomes in nAMD
08/08/24 • 26 min
In this episode, my guests Vision Academy and Barometer Program member Professor Jean-François Korobelnik, Professor and Head of the Ophthalmology Department at the University Hospital of Bordeaux in France, and Vision Academy member Professor Robyn Guymer, Deputy Director at the Centre for Eye Research and Professor of Ophthalmic at the University of Melbourne in Australia, discuss considerations for devising flexible and individualized treatment regimens for patients with nAMD with residual fluid.
Using examples from their own clinical experience, Professors Korobelnik and Guymer explore the nuanced relationship between efficacy of anti-VEGF treatment and location and presence (or absence) of fluid in patients with nAMD.
The Vision Academy Viewpoint providing recommendations for the assessment and monitoring of fluid status can be found on the website, along with other viewpoints and resources. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.
Speaker disclosures:
Professor Jean-François Korobelnik
Consultancy: Abbvie, Allergan, Apellis, Bayer, Carl Zeiss Meditec, Janssen, NanoRetina, Roche, and Théa.
Professor Robyn Guymer
Advisory boards and/or Consultancy: Apellis, Bayer, Belite Bio, Boehringer Ingelheim Pharmaceuticals, Character Bioscience, Genentech, Novartis, Ocular Therapeutix, and Roche.
Further information on residual fluid:
Arnold J.J, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/
Lek JJ., et al. Interpretation of subretinal fluid using OCT in intermediate age-related macular degeneration. Ophthalmol Retina. 2018. https://www.sciencedirect.com/science/article/abs/pii/S2468653017307315?via%3Dihub
Hahn P, Eliott D, eds. 2021 Global Trends in Retina Survey. 2021. https://www.asrs.org/content/documents/20
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
In this episode, my guests Vision Academy and Barometer Program member Professor Jean-François Korobelnik, Professor and Head of the Ophthalmology Department at the University Hospital of Bordeaux in France, and Vision Academy member Professor Robyn Guymer, Deputy Director at the Centre for Eye Research and Professor of Ophthalmic at the University of Melbourne in Australia, discuss considerations for devising flexible and individualized treatment regimens for patients with nAMD with residual fluid.
Using examples from their own clinical experience, Professors Korobelnik and Guymer explore the nuanced relationship between efficacy of anti-VEGF treatment and location and presence (or absence) of fluid in patients with nAMD.
The Vision Academy Viewpoint providing recommendations for the assessment and monitoring of fluid status can be found on the website, along with other viewpoints and resources. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.
Speaker disclosures:
Professor Jean-François Korobelnik
Consultancy: Abbvie, Allergan, Apellis, Bayer, Carl Zeiss Meditec, Janssen, NanoRetina, Roche, and Théa.
Professor Robyn Guymer
Advisory boards and/or Consultancy: Apellis, Bayer, Belite Bio, Boehringer Ingelheim Pharmaceuticals, Character Bioscience, Genentech, Novartis, Ocular Therapeutix, and Roche.
Further information on residual fluid:
Arnold J.J, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/
Lek JJ., et al. Interpretation of subretinal fluid using OCT in intermediate age-related macular degeneration. Ophthalmol Retina. 2018. https://www.sciencedirect.com/science/article/abs/pii/S2468653017307315?via%3Dihub
Hahn P, Eliott D, eds. 2021 Global Trends in Retina Survey. 2021. https://www.asrs.org/content/documents/20
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Previous Episode
Pachychoroid: Current concepts on clinical features and pathogenesis
In this episode, Vision Academy members Professor Annabelle Okada, Professor of Ophthalmology and Director of the Ocular Inflammation Service and the Macular Disease Service at the Kyorin University School of Medicine in Japan, and Professor Ian Pearce, Consultant Ophthalmologist and Vitreoretinal Surgeon at the Royal Liverpool University Hospital in the UK, discuss the pachychoroid spectrum.
Using practical examples from their own clinics, they explore how accurate diagnosis, monitoring, prognosis and treatment decisions depend upon consensus descriptions of clinical, morphological and epidemiological characteristics disorders on the pachychoroid spectrum. They also discuss multimodal imaging and barriers to its implementation in clinical practice.
The Vision Academy Viewpoint covering the consensus on the definition of pachychoroid and details on the management of the pathologies included in this spectrum, and other important viewpoints and resources, can be found here. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing the importance of characterizing macular neovascularization subtypes in nAMD to optimize treatment outcomes, and how we as ophthalmologists can best choose the optimal anti-VEGF therapy regimen for our patients with retinal vascular diseases. SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Speaker disclosures:
Professor Annabelle Okada
Consultancy: Bayer, Chugai, Novartis, Roche, and Santen Pharmaceutical.
Professor Ian Pearce
Consultancy: Apellis, Bayer, Novartis, and Roche.
Further information on Pachychoroid:
Castro-Navarro V., et al. Pachychoroid: current concepts on clinical features and pathogenesis. Graefes Arch Clin Exp Ophthalmol.2020.
Warrow DJ., Hoang QV. and Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013.
Miyake M., et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015.
Li Y., et al. Polypoidal choroidal vasculopathy in adult Chinese: the Beijing Eye Study. Ophthalmology. 2014.
Li Y., et al. Prevalence and associations of central serous chorioretinopathy in elderly Chinese. The Beijing Eye Study 2011. Acta Ophthalmol. 2016.
Manayath GJ., et al. Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy: pachychoroid spectrum of diseases. Retina
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Next Episode
Equal Vision – Women in Ophthalmology
My guests for this episode are Professor Sobha Sivaprasad, Consultant Ophthalmologist at Moorfields Eye Hospital and Professor of Retinal Clinical Studies at the UCL Institute of Ophthalmology in London, and Professor Gemmy Cheung, Professor and Senior Consultant Ophthalmologist at the Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore. In this special episode, we discuss our experiences as women working in ophthalmology, and the advice we would give to young, aspiring ophthalmologists.
We also talk about what it meant to us to be named on The Ophthalmologist’s Power List, and how the next generation of ophthalmologists can be empowered through mentorship. We recommend visiting the Vision Academy Program website and nAMD Barometer Program website. We participate in these Programs to help develop important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice.
If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy: AbbVie, Bayer, Beyeonics, Syneos, Ripple, Iveric Bbio, Johnson & Johnson, Ocuphire, Iqvia, Notal Vision, Novartis, and Roche.
Professor Sobha Sivaprasad
Consultancy: AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Phamaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi; Research grants: Bayer and Boehringer Ingleheim.
Professor Gemmy Cheung
Consultancy: Bayer, Roche, and Novartis.
August 2024 PP-PF-OPHT-ALL-0164-1
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing
'A Chat with Anat' is a series for ophthalmologists who are interested in improving delivery of care and improved outcomes for patients living with neovascular age-related macular degeneration (nAMD). I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss key topics on patient-focused care. This podcast series is sponsored and organised by Bayer and produced by A
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/a-chat-with-anat-473558/impact-of-residual-fluid-on-treatment-outcomes-in-namd-68216679"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to impact of residual fluid on treatment outcomes in namd on goodpods" style="width: 225px" /> </a>
Copy